20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Cybin Inc. Common Stock (HELP) operates in the BIOTECHNOLOGY industry and is headquartered in Toronto, Canada with about 100 employees. Its market capitalization is roughly $904 million. In the fiscal year ended 2026-03-31, HELP reported ($45M) in revenue and ($147M) in net income.
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 | 2018-03-31 | 2017-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $1M | ($45M) | $0M | ($18M) | $0M | $0M | $1M | — | — | — | — |
| Gross Profit | $1M | ($45M) | $0M | ($19M) | $0M | $0M | $0M | — | — | — | — |
| Gross Margin % | 89.9% | 100.3% | -100.0% | 102.3% | -100.0% | -100.0% | -36.0% | — | — | — | — |
| Operating Income (EBIT) | ($177M) | ($142M) | ($143M) | ($79M) | ($52M) | ($64M) | ($31M) | ($2M) | $0M | $0M | $0M |
| Operating Margin % | -13639.1% | 317.1% | -30310.4% | 434.4% | -20523.9% | -38053.2% | -3592.0% | — | — | — | — |
| Net Income | ($183M) | ($147M) | ($113M) | ($78M) | ($47M) | ($68M) | ($32M) | ($2M) | $0M | $0M | $0M |
| Net Margin % | -14108.4% | 329.1% | -23956.0% | 430.2% | -18919.2% | -40314.1% | -3729.2% | — | — | — | — |
| EBITDA | ($177M) | ($142M) | ($143M) | ($78M) | ($51M) | ($64M) | ($31M) | $0M | $0M | $0M | $0M |
| Earnings Per Share (EPS) | $-3.52 | $-4.23 | $-5.59 | $-3.90 | $-9.73 | $-15.36 | $-12.24 | $-1.48 | $-0.28 | $-0.69 | $-0.35 |
| Shares Outstanding (M) | 52M | 35M | 20M | 20M | 5M | 4M | 3M | 1M | 0M | 0M | 0M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $1M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | $0M | $1M | $0M | $0M | $0M | — | $0M | $0M |
| Gross Margin % | — | 97.7% | — | — | — | — | — | — |
| Operating Income (EBIT) | ($48M) | ($48M) | ($41M) | ($40M) | ($25M) | ($33M) | ($32M) | ($58M) |
| Operating Margin % | — | -3684.3% | — | — | — | — | — | — |
| Net Income | ($47M) | ($47M) | ($43M) | ($47M) | ($25M) | ($31M) | ($11M) | ($57M) |
| Net Margin % | — | -3617.8% | — | — | — | — | — | — |
| EBITDA | ($48M) | ($48M) | ($41M) | ($40M) | ($25M) | — | ($32M) | ($58M) |
| Earnings Per Share (EPS) | $-0.89 | $-0.93 | $-1.76 | $-1.94 | $-1.10 | $-1.41 | $-0.54 | $-2.84 |
| Shares Outstanding (M) | 52M | 50M | 24M | 24M | 22M | 22M | 20M | 20M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 | 2018-03-31 | 2017-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($153M) | ($132M) | ($101M) | ($69M) | ($47M) | ($45M) | ($19M) | $0M | $0M | $0M | $0M |
| Capital Expenditures (CapEx) | $2M | $1M | $2M | $1M | $3M | $1M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($155M) | ($134M) | ($103M) | ($70M) | ($51M) | ($46M) | ($19M) | $0M | $0M | $0M | $0M |
| FCF Margin % | -11900.9% | 299.4% | -21865.9% | 383.6% | -20213.9% | -27257.4% | -2228.9% | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($36M) | ($37M) | ($32M) | ($48M) | ($22M) | ($21M) | ($27M) | ($26M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $1M | $0M | $1M | $0M | $0M |
| Free Cash Flow (FCF) | ($36M) | ($37M) | ($32M) | ($49M) | ($22M) | ($22M) | ($27M) | ($26M) |
| FCF Margin % | — | -2859.2% | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 | 2018-03-31 | 2017-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $259M | $252M | $259M | $302M | $54M | $84M | $92M | $2M | $0M | $0M | $0M |
| Cash & Cash Equivalents | $166M | $158M | $135M | $209M | $17M | $54M | $64M | $2M | $0M | $0M | $0M |
| Total Liabilities | $18M | $19M | $21M | $10M | $6M | $8M | $6M | $0M | $0M | $0M | $0M |
| Total Debt (Short + Long-Term) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Total Shareholders' Equity | $242M | $232M | $237M | $292M | $48M | $76M | $86M | $1M | $0M | $0M | $0M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive HELP viewer.
About TickerBase · Data methodology & sources · Privacy · Terms